0001645113-23-000025.txt : 20230302
0001645113-23-000025.hdr.sgml : 20230302
20230302164932
ACCESSION NUMBER: 0001645113-23-000025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230228
FILED AS OF DATE: 20230302
DATE AS OF CHANGE: 20230302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GROENHUYSEN WILHELMUS CM
CENTRAL INDEX KEY: 0001264783
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37565
FILM NUMBER: 23699878
MAIL ADDRESS:
STREET 1: C/O NAVTEQ CORPORATION
STREET 2: 222 MERCHANDISE MART STE 900
CITY: CHICAGO
STATE: IL
ZIP: 60654
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NovoCure Ltd
CENTRAL INDEX KEY: 0001645113
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: NO. 4 THE FORUM
STREET 2: GRENVILLE STREET
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4UF
BUSINESS PHONE: 44 (0)15 3475 6700
MAIL ADDRESS:
STREET 1: NO. 4 THE FORUM
STREET 2: GRENVILLE STREET
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4UF
FORMER COMPANY:
FORMER CONFORMED NAME: Novocure Ltd
DATE OF NAME CHANGE: 20150615
4
1
wf-form4_167779374758834.xml
FORM 4
X0306
4
2023-02-28
0
0001645113
NovoCure Ltd
NVCR
0001264783
GROENHUYSEN WILHELMUS CM
C/O NOVOCURE INC.,
1550 LIBERTY RIDGE DRIVE, SUITE 115
WAYNE
PA
19087
0
1
0
0
Chief Operating Officer
Ordinary Shares
2023-02-28
4
A
0
21653
0
A
186779
D
Ordinary Shares
2023-03-01
4
S
0
2164
76.3624
D
184615
D
Options to Buy Ordinary Shares
76.97
2023-02-28
4
A
0
36013
76.97
A
2024-02-28
2033-02-27
Ordinary Shares
36013.0
36013
D
Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Options to buy 36,013 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
By: /s/ Steven Robbins, Attorney in Fact for Wilhelmus CM Groenhuysen
2023-03-02